COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Protocol No
ECOG-EA9152-ALL
Principal Investigator
Ehab Atallah
Phase
I/II
Summary
This study is being done to determine what effects (good and bad) the therapy venetoclax has on this type of cancer (acute lymphoblastic leukemia, also known as ALL). This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed acute lymphoblastic leukemia. It is hoped that venetoclax will help liposomal vincristine work better to kill the ALL, but it has not yet been proven.
Description
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL